SOUTH SAN FRANCISCO, Calif., May 2 /PRNewswire/ -- XDx, Inc., a molecular diagnostics company, today announced the appointment of Vikram Jog to the position of chief financial officer (CFO). In this newly established position, Jog will leverage his significant executive-level finance and management experience to oversee the company's financial functions and to help the company achieve its financial goals, following the launch of its first offering -- AlloMap(TM) molecular expression testing for heart transplant patient management.
"Vikram has a wealth of industry experience and well-developed relationships, both within the industry and the financial community, making him a great asset to XDx," said Pierre Cassigneul, president and chief executive officer of XDx. "We are confident that Vikram's appointment will have a positive impact on the future of this company, helping to position us for continued growth and success."
Jog brings more than 25 years of finance experience, including roles at several public corporations. Most recently, he served as vice president of finance for Celera Genomics and Celera Diagnostics, where he was responsible for the financial functions of these two Applera Corporation businesses. Prior to this, Jog served as vice president of planning and corporate controller for Applera Corporation.
"XDx's broad-based technology platform has enormous potential, and I'm extremely excited to be part of the team brining this innovation to the industry," said Jog.
Prior to joining Applera Corporation, Jog worked as vice president and controller at Hercules Incorporated, a specialty chemicals provider based in Wilmington, Del. For 13 years prior to that, he was successively with Coopers & Lybrand and Price Waterhouse, which have since merged to become PricewaterhouseCoopers LLP.
Jog received a Bachelor of Commerce degree from Delhi University in Delhi, India, and an MBA degree from Temple University in Philadelphia, Pa. Jog is a member of the American Institute of Certified Public Accountants and the Financial Executives Institute.
About XDx Inc.
Founded in 2000, XDx Inc. is a molecular diagnostics company based in South San Francisco, Calif. Setting the stage for a new era in personalized medicine, XDx is one of the first companies to develop and commercialize practical applications built on insights from the Human Genome Project. The company has developed a proprietary new method for non-invasively monitoring the immune system by measuring gene expression in a patients' peripheral blood. The technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering, immune-mediated diseases. More information can be found at http://www.xdx.com/.
About AlloMap(TM) Molecular Expression Testing
AlloMap molecular expression testing is a non-invasive method for determining the risk of rejection in heart transplant recipients. The test translates the complex signals of the immune system's multiple genes and pathways, specifically those associated with heart transplant rejection, into an objective, actionable score. AlloMap testing enables clinicians -- for the first time -- to monitor the immune system early, identifying the risk of tissue damage before it occurs, and to manage immunosuppressive therapy proactively
The clinical value of AlloMap testing was demonstrated in a landmark multi-center, prospective study known as Cardiac Allograft Rejection Gene Expression Observational (CARGO). In addition, clinical trials are currently underway to determine the value of AlloMap testing in lung transplantation. The company also plans to evaluate the utility of this technology in autoimmune conditions such as lupus and Crohn's disease. More information can be found at http://www.allomap.com/.
XDx, Inc.CONTACT: Corporate, Tammy Reilly of XDx, +1-650-624-0120, or Media,Kelly McKenna of MS&L, +1-415-364-3840, for XDx
Web site: http://www.xdx.com/
